PEOPLE - Changes at FlowMedica:
This article was originally published in Clinica
Executive Summary
FlowMedica (Fremont, California) has named Gordon Snyder vice-president of sales, as the company moves to commercialise its products. The firm develops intervascular systems to deliver therapeutic agents direct to the kidneys via the renal arteries (targeted renal therapy - TRT) to prevent and treat kidney dysfunction resulting from radiographic contrast media, administered during coronary intervention and diagnostic procedures. Prior to joining FlowMedica, Mr Snyder had managed sales at Novoste and Medtronic among other device companies.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.